JPMorgan analyst Anupam Rama says Vera Therapeutics (VERA) shares closed down 20% on Friday, driven by Otsuka’s announcement that the biologics license application for sibeprenlimab in IgA nephropathy would be filed with a pre-filled syringe that can be administered at home. The firm views the selloff as overblown, saying it does not see Otsuka’s strategy as a “lay-up by any means and, certainly, there is regulatory risk.” Importantly, Vera’s atacicept is the only b-cell modulator to have at-home exposure over a two-year period and that has studied this regimen in a pivotal study, the analyst tells investors in a research note. JPMorgan continues to see a trade into the mid-$40s per share for Vera shares on positive ORIGIN-3 data. It keeps an Overweight rating on the name.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- 3 Best Stocks to Buy Now, 2/18/2025, According to Top Analysts
- Buy Rating Affirmed for Vera Therapeutics Amid Promising Atacicept Prospects and Market Overreaction Concerns
- Vera reaction to competitor IgAN update ‘overdone,’ says Goldman Sachs
- Vera Therapeutics weakness on Otsuka plans ‘makes no sense,’ says Wells Fargo
- Vera Therapeutics initiated with an Outperform at Wolfe Research